734 related articles for article (PubMed ID: 22069564)
1. Toxin-based therapeutic approaches.
Shapira A; Benhar I
Toxins (Basel); 2010 Nov; 2(11):2519-83. PubMed ID: 22069564
[TBL] [Abstract][Full Text] [Related]
2. Anthrax fusion protein therapy of cancer.
Frankel AE; Powell BL; Duesbery NS; Vande Woude GF; Leppla SH
Curr Protein Pept Sci; 2002 Aug; 3(4):399-407. PubMed ID: 12370003
[TBL] [Abstract][Full Text] [Related]
3. Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer.
Weidle UH; Tiefenthaler G; Schiller C; Weiss EH; Georges G; Brinkmann U
Cancer Genomics Proteomics; 2014; 11(1):25-38. PubMed ID: 24633317
[TBL] [Abstract][Full Text] [Related]
4. Immunotoxins in cancer therapy: Review and update.
Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
[TBL] [Abstract][Full Text] [Related]
5. Recombinant toxins as novel therapeutic agents.
Pastan I; Chaudhary V; FitzGerald DJ
Annu Rev Biochem; 1992; 61():331-54. PubMed ID: 1497314
[No Abstract] [Full Text] [Related]
6. Bacterial Toxins for Cancer Therapy.
Zahaf NI; Schmidt G
Toxins (Basel); 2017 Jul; 9(8):. PubMed ID: 28788054
[TBL] [Abstract][Full Text] [Related]
7. Chimeric fusion proteins--Pseudomonas exotoxin-based.
Kreitman RJ
Curr Opin Investig Drugs; 2001 Sep; 2(9):1282-93. PubMed ID: 11717817
[TBL] [Abstract][Full Text] [Related]
8. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
Kreitman RJ
BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
[TBL] [Abstract][Full Text] [Related]
9. Immunotoxins in the treatment of hematologic malignancies.
Kreitman RJ; Pastan I
Curr Drug Targets; 2006 Oct; 7(10):1301-11. PubMed ID: 17073592
[TBL] [Abstract][Full Text] [Related]
10. Patents on immunotoxins and chimeric toxins for the treatment of cancer.
Bachran C; Sutherland M; Bachran D; Fuchs H
Recent Pat Drug Deliv Formul; 2007; 1(2):105-15. PubMed ID: 19075878
[TBL] [Abstract][Full Text] [Related]
11. Immunotoxins: is there a clinical value?
Gottstein C; Winkler U; Bohlen H; Diehl V; Engert A
Ann Oncol; 1994; 5 Suppl 1():97-103. PubMed ID: 7826425
[TBL] [Abstract][Full Text] [Related]
12. Advances in anticancer immunotoxin therapy.
Alewine C; Hassan R; Pastan I
Oncologist; 2015 Feb; 20(2):176-85. PubMed ID: 25561510
[TBL] [Abstract][Full Text] [Related]
13. Immunotoxins.
Press OW
Biotherapy; 1991; 3(1):65-76. PubMed ID: 2009215
[TBL] [Abstract][Full Text] [Related]
14. Immunotoxins: the role of the toxin.
Antignani A; Fitzgerald D
Toxins (Basel); 2013 Aug; 5(8):1486-502. PubMed ID: 23965432
[TBL] [Abstract][Full Text] [Related]
15. Antibody-toxin conjugates: a new approach to cancer therapy.
McIntosh DP
Adv Biotechnol Processes; 1984; 3():111-39. PubMed ID: 6399840
[No Abstract] [Full Text] [Related]
16. Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology.
Shilova O; Shramova E; Proshkina G; Deyev S
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34067057
[TBL] [Abstract][Full Text] [Related]
17. Anti-cancer Immunotoxins, Challenges, and Approaches.
Dashtiahangar M; Rahbarnia L; Farajnia S; Salmaninejad A; Shabgah AG; Ghasemali S
Curr Pharm Des; 2021; 27(7):932-941. PubMed ID: 33023437
[TBL] [Abstract][Full Text] [Related]
18. Urokinase receptor (uPAR) ligand based recombinant toxins for human cancer therapy.
de Virgilio M; Silvestris F
Curr Pharm Des; 2011; 17(19):1979-83. PubMed ID: 21711232
[TBL] [Abstract][Full Text] [Related]
19. Small molecule toxins targeting tumor receptors.
Dyba M; Tarasova NI; Michejda CJ
Curr Pharm Des; 2004; 10(19):2311-34. PubMed ID: 15279611
[TBL] [Abstract][Full Text] [Related]
20. Bacterial Toxins for Oncoleaking Suicidal Cancer Gene Therapy.
Pahle J; Walther W
Recent Results Cancer Res; 2016; 209():95-110. PubMed ID: 28101690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
